10:06 AM EDT, 08/21/2024 (MT Newswires) -- Oragenics ( OGEN ) said Wednesday it had completed the spray-dried formulation for ONP-002, its potential treatment for concussion, and loaded the powder into an intranasal device in anticipation of a phase 2a clinical trial.

The company said the spray-dried nanoparticle formulation would be used in the planned phase 2a study to be conducted in Australia.

Oragenics ( OGEN ) said it has also initiated a stability program for both the drug formula alone and within the intranasal device.

Price: 0.92, Change: -0.01, Percent Change: -0.85